English
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Page 1 from 18 results
Drug delivery systems and methods for treating cancer using gold nanoparticles coated with citrate ions, frankincense and myrrh
Only registered users can translate articles
Log In/Sign up
BACKGROUND
Conventional treatments for cancer, such as chemotherapy and radiation therapy, can be used to selectively kill rapidly dividing cancer cells in the body. Conventional treatments, however, exhibit poor target specificity. The efficacy of chemotherapy, for example, is hindered, because
Stable pharmaceutical composition of Etanercept in a phosphate citrate buffer with glycine as an anti-aggregating agent
Only registered users can translate articles
Log In/Sign up
FIELD OF INVENTION
The invention provides stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc). The invention also provides methods of manufacturing the composition, method of administration and kits containing the same.
BACKGROUND OF
Urinary polyamines as prostate cancer detection biomarkers
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The present disclosure relates to methods for the detection and quantization of urinary polyamines and compositions for use therein. The methods and compositions described herein are useful in diagnosis of prostate cancer in patient.
BACKGROUND OF THE INVENTION
Prostate cancer
Compositions and methods for treating cancer
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The present invention relates to compositions comprising inhibitors of ATP citrate lyase and/or tricarboxylate transporter and methods of using such compositions to treat individuals who have been diagnosed with cancer.
BACKGROUND OF THE INVENTION
Each year, more than one
Anemia of cancer improving/prophylactic agent
Only registered users can translate articles
Log In/Sign up
CROSS REFERENCE TO RELATED APPLICATIONS
This is a national stage application based on PCT/JP2012/076020, filed on Oct. 5, 2012, which claims priority to Japanese Patent Application Nos. 2011-225383, filed on Oct. 12, 2011, and 2012-081346, filed on Mar. 30, 2012. This application claims the priority
Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
The leading cause of pulmonary and cerebral embolism is thrombophlebitis. Thromboembolism is caused by abnormalities of the blood vessel, the blood or the circulation resulting the formation of blood clots called thrombi. Within a short period of time, many of these blood
Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
This invention relates generally to the chemical synthesis of steroids, and more particularly relates to the synthesis of anti-estrogenic and other therapeutic steroids such as 3-hydroxy-7.alpha.-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]- -19-norpregna-1,3,5(10)triene
Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
This invention relates generally to the chemical synthesis of steroids, and more particularly relates to the synthesis of anti-estrogenic and other therapeutic steroids such as 3-hydroxy-7.alpha.-methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]- 19-norpregna-1,3,5(10)triene
Complex of transferrin with ruthenium for medical applications
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
The present invention relates to novel ruthenium labeled transferrin compounds, methods for preparing and purifying them, and their uses in nuclear medicine as a diagnostic tool, as well as possible uses in the treatment of tumors and abscesses.
The prior art discloses
Method for differentiating the source of occult gastrointestinal bleeding
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
The present invention relates to a method for differentiating the source of occult gastrointestinal bleeding.
The common screening test for occult gastrointestinal bleeding is to test for fecal occult blood (FOB). An FOB test involves placing a sample of stool onto a
Micronutrient formulations for radiation applications
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to a use of micronutrient formulations to reduce the effects of radiation on humans.
Description of the Related Art
Ionizing radiation (X-rays and gamma rays) has proven to be a double-edged sword in clinical Medicine since
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra- zol-4-yl]-urea
Only registered users can translate articles
Log In/Sign up
TECHNICAL FIELD
This invention relates to combinations comprising (or consisting essentially of) one or more compounds of the formula (I') or (I) as defined herein (so including one or more specific salts of the compound 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyra-
Crystalline forms of kinase inhibitors
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The present invention relates to crystalline forms of citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-- 3-yl}phenyl)-N'-(3-fluorophenyl)urea, processes for preparing the crystalline forms, pharmaceutical formulations thereof, and
Crystal forms of kinase inhibitors
Only registered users can translate articles
Log In/Sign up
FIELD OF THE INVENTION
The present invention relates to crystalline forms of citrate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-- 3-yl}phenyl)-N'-(3-fluorophenyl)urea, processes for preparing the crystalline forms, pharmaceutical formulations thereof, and
Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]- isothiazole-4-carboxylic acid amide and method of production
Only registered users can translate articles
Log In/Sign up
BACKGROUND OF THE INVENTION
This invention relates to salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]- isothiazole-4-carboxylic acid amide having the formula: ##STR2##
Formula I in its free base form is described in co-pending U.S. Ser. No. 09/316,837, filed
The most complete medicinal herbs database backed by science
- Works in 55 languages
- Herbal cures backed by science
- Herbs recognition by image
- Interactive GPS map - tag herbs on location (coming soon)
- Read scientific publications related to your search
- Search medicinal herbs by their effects
- Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against.
*All information is based on published scientific research
